2017 Pediatric Rheumatology Symposium

May 17-20, 2017. Houston, Texas.

View by Number View by Title View Sessions

View by Date

Jump to: View All • [a] b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 53

A Prospective Study to Assess for Changes in Mood with Initiation of Anti-TNF therapy: A Pilot Study
Abstract Number: 155

A Single Center Review of Health Related Quality of Life in Children with Systemic Lupus Erythematosus Using the Pediatric Quality of Life Inventory Version 4.0 Generic Core Scale
Abstract Number: 89

Abatacept as Adjunct Therapy for the Calcinosis of Juvenile Dermatomyositis: A Single-Center Experience
Abstract Number: 7

Activation of Immature, Transitional B cells by Integrated BCR, TLR and TACI signals promotes systemic autoimmunity in high BAFF settings
Abstract Number: 123

Acupuncture for Pediatric Chronic Pain Relief: A Review
Abstract Number: 146

Age-Related Differences in Neuronal High Mobility Group Box-1 and Resolvin D1 Receptors in Collagen-Induced Arthritis
Abstract Number: 134

Akkermansia Muciniphila May Be Permissive to Arthritis in the K/BxN Mouse Model of Arthritis
Abstract Number: 33

An extracellular ionic milieu renders human granulocytic S100A12 into a pro-inflammatory TLR4-binding alarmin
Abstract Number: 15

An Internet-based Self-management Program for Adolescents with Juvenile Idiopathic Arthritis – A Randomized Controlled Trial
Abstract Number: 58

Analysis and Implications of Non-Invasive Knee Acoustical Emissions in Juvenile Idiopathic Arthritis
Abstract Number: 17

Anti-endothelial cell antibodies in juvenile dermatomyositis
Abstract Number: 115

Anti-Phospholipid Antibodies in Children with Down Syndrome
Abstract Number: 76

Applying 2016 MAS Criteria to Systemic onset Juvenile Idiopathic Arthritis Patients with Diagnosis of Macrophage Activation Syndrome
Abstract Number: 116

Arthritis as First Presenting Symptom of Inflammatory Bowel Disease: A Case Control Study
Abstract Number: 27

Assessing the Safety of Kidney Biopsies Performed on Childhood-onset Systemic Lupus Erythmatosus Patients
Abstract Number: 87

Assessment of Endothelial Dysfunction and Atherogenic Risk Factors in Children with Juvenile Dermatomyositis
Abstract Number: 106

Atypical manifestations and main misdiagnoses of Takayasu’s arteritis in childhood: a multicenter study of 71 patients

Jump to: View All • [a] b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].